The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
 
Marc S. Ernstoff
Stock and Other Ownership Interests - GE Healthcare
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; EMD Serono; Lion Biotechnologies; Omniseq
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst)
 
Wen Wee Ma
Consulting or Advisory Role - Merrimack
Research Funding - Athenex (Inst); Merrimack (Inst)
 
Frank Yung-Chin Tsai
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Walid Kamoun
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
J. Marc Pipas
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
Sharon Chen
No Relationships to Disclose
 
Sergio Santillana
Employment - ARIAD; Merrimack; Takeda
Leadership - ARIAD; Merrimack
Stock and Other Ownership Interests - ARIAD; Merrimack; Takeda
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - ARIAD; Merrimack; Takeda
 
Vasileios Askoxylakis
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack